热门资讯> 正文
Horizon Space Acquisition II宣布与SL Bio达成业务合并协议
2025-05-12 20:54
- Horizon Space Acquisition II Corp. (NASDAQ:HSPT), a publicly traded special purpose acquisition company, and SL Bio, a clinical-stage biomedical company specialized in developing groundbreaking cellular and gene therapies for skin care and cancer recovery, said they have entered into a definitive business combination agreement.
- Upon completion of the business combination of HSPT and SL Bio and related transactions pursuant to the Business Combination Agreement, SL Science Holding Limited, a Cayman Islands exempted company newly formed for purposed of effecting the proposed transaction will be listed on Nasdaq.
- The proposed transactions are expected to close by late 2025.
- Upon completion of the transactions, PubCo will be led by CEO and Chairman, William Wang. Johnson Lau will serve as CFO and Ethan Shen will serve as Chief Technology Officer.
- Source: Press Release
More on Horizon Space Acquisition II Corp.
- Financial information for Horizon Space Acquisition II Corp.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
